Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Bianca Devitt"'
Autor:
Wee Kheng Soo, PhD, Madeleine King, ProfPhD, Alun Pope, PhD, Christopher Steer, MBBS, Bianca Devitt, PhD, Susan Chua, MBBS, Phillip Parente, MBBS, Ian D Davis, ProfPhD, Pēteris Dārziņš, ProfPhD
Publikováno v:
The Lancet. Healthy Longevity, Vol 2, Iss 1, Pp e24-e33 (2021)
Summary: Background: Functional assessment of patients with cancer can be challenging and is often undertaken by the clinician with minimal direct input from the patient. We developed and aimed to validate the Elderly Functional Index (ELFI), a compo
Externí odkaz:
https://doaj.org/article/80c6fa8279d04e8899479854abdc5ca3
Autor:
Sheau Wen Lok, Richard De Boer, Sally Baron‐Hay, Peter Button, Bianca Devitt, Benjamin C. Forster, Peter Fox, Michael Harold, Sahisha Ketheeswaran, Ganessan Kichenadasse, Belinda E. Kiely, Gavin Marx, Louise Nott, Laura Pellegrini, Ali Tafreshi, Peter Gibbs
Publikováno v:
International Journal of Cancer. 152:267-275
The pertuzumab study in the neoadjuvant setting for HER2+ nonmetastatic breast cancer in Australia (PeRSIA-ML39622) is an analysis of safety and effectiveness data from the pertuzumab patient registry. Although the prognosis of patients with early st
Autor:
Melinda L. Telli, Irene Wapnir, Bianca Devitt, Katharine Cuff, Hatem Soliman, Shaveta Vinayak, David A. Canton, Christopher G. Twitty, Sunny Xie, Ying Lu, Donna Bannavong, Bridget O'Keeffe, Sandra Aung, Rohit Joshi
Publikováno v:
Cancer Research. 82:P2-14
BACKGROUND: Electroporated plasmid interleukin-12 (tavokinogene telseplasmid; TAVO-EP) delivered to accessible tumors by intratumoral injection induces sustained local expression of IL-12. IL-12 is a potent immunoregulatory cytokine that plays a key
Autor:
Sheau Wen Lok, Richard De Boer, Sallt Baron-Hay, Peter Button, Bianca Devitt, Benjamin Forster, Peter Fox, Michael Harold, Sahisha Ketheeswaran, Ganessan Kichenadasse, Belinda E Kiely, Gavin Marx, Louise Nott, Laura Pellegrini, Ali Tafreshi, Peter GIbbs
Publikováno v:
Cancer Research. 82:P2-13
BACKGROUND Adding pertuzumab to trastuzumab in patients (pts) with HER2+ breast cancer improves pathological complete response (pCR) rates. Pertuzumab + trastuzumab + chemotherapy is approved in Australia as neoadjuvant therapy in early stage (>2 cm
Publikováno v:
Cancer Research. 81:PS13-36
Background: Scalp cooling minimises chemotherapy-induced alopecia (CIA) which may reduce distress, improve quality of life and body image. This study assesses scalp-cooling efficacy in women receiving chemotherapy for early and advanced breast and ov
Autor:
Rachel Wong, Bianca Devitt, Javier Torres, Ian M. Collins, Sheau Wen Lok, Richard De Boer, Laeeq Malik, Gary Richardson, Angelyn Anton, Louise M. Nott, Belinda Yeo, Nicole Evans, Peter Gibbs, Frances Barnett, Sarah L M Greenberg
Publikováno v:
Cancer Research. 81:PS6-35
BackgroundThe development of anti-human epidermal growth factor receptor 2 (HER2) therapies has significantly improved disease outcomes in patients with HER2-positive advanced breast cancer (ABC). However, elderly patients are persistently under-repr
Publikováno v:
Cancer Research. 83:P5-04
Background: Breast cancer is the second most common cancer occurring during pregnancy with limited evidence for appropriate staging (1,2). A Delphi study was performed to develop consensus guidelines. Methods: Guideline recommendations were construct
Autor:
Alun Pope, Madeleine King, Susan Chua, Bianca Devitt, Christopher Steer, Ian D. Davis, Phillip Parente, Wee Kheng Soo, Pēteris Dārziņš
Publikováno v:
The Lancet. Healthy Longevity, Vol 2, Iss 1, Pp e24-e33 (2021)
Summary: Background: Functional assessment of patients with cancer can be challenging and is often undertaken by the clinician with minimal direct input from the patient. We developed and aimed to validate the Elderly Functional Index (ELFI), a compo
Publikováno v:
Cancer Research. 80:P1-17
Background: Addition of taxanes to adjuvant chemotherapy provides survival benefit in patients with early breast cancer (EBC). Intensifying adjuvant regimens with taxanes leads to increased toxicity, including higher rates of sensory peripheral neuro
Autor:
Irene Wapnir, Shaveta Vinayak, Melinda L. Telli, Bianca Devitt, Katharine Cuff, Hatem Soliman, David A. Canton, Rohit Joshi, Kellie Malloy Foerter, Christopher G. Twitty
Publikováno v:
Cancer Research. 80:P3-09
BACKGROUND: Anti-PD-1 checkpoint inhibitor (CPI) monotherapy has demonstrated modest activity in pre-treated mTNBC, with single digit objective response rates (ORR) observed. Our prior data suggests that local electroporation after intratumoral admin